Karapanagiotou EM - Search Results

1

Therapy-induced toxicity of the lungs: an overview.

Charpidou AG, Gkiozos I, Tsimpoukis S, Apostolaki D, Dilana KD, Karapanagiotou EM, Syrigos KN. Charpidou AG, et al. Among authors: karapanagiotou em. Anticancer Res. 2009 Feb;29(2):631-9. Anticancer Res. 2009. PMID: 19331213 Free article. Review.

2

Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.

Karapanagiotou EM, Boura PG, Papamichalis G, Konstantinou M, Sepsas E, Chamalakis G, Simsiris P, Gkiozos I, Syrigos KN. Karapanagiotou EM, et al. Anticancer Res. 2009 Oct;29(10):4297-301. Anticancer Res. 2009. PMID: 19846990 Free article. Clinical Trial.

3

The need for third-line treatment in non-small cell lung cancer: an overview of new options.

Syrigos KN, Saif MW, Karapanagiotou EM, Oikonomopoulos G, De Marinis F. Syrigos KN, et al. Among authors: karapanagiotou em. Anticancer Res. 2011 Feb;31(2):649-59. Anticancer Res. 2011. PMID: 21378351 Review.

4

A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.

Karapanagiotou EM, Charpidou A, Tzannou I, Dilana K, Kotteas E, Tourkantonis I, Kosmas E, Provata A, Syrigos K. Karapanagiotou EM, et al. Med Oncol. 2008;25(3):303-8. doi: 10.1007/s12032-007-9036-9. Epub 2008 Jan 17. Med Oncol. 2008. PMID: 18204976 Clinical Trial.

5

Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.

Karapanagiotou EM, Pelekanou E, Charpidou A, Tsaganos T, Anagnostou V, Plachouras D, Giamarellos-Bourboulis EJ, Syrigos KN. Karapanagiotou EM, et al. Anticancer Res. 2008 Mar-Apr;28(2B):1411-5. Anticancer Res. 2008. PMID: 18505088 Free article.

6

Head and neck cancer in the elderly: an overview on the treatment modalities.

Syrigos KN, Karachalios D, Karapanagiotou EM, Nutting CM, Manolopoulos L, Harrington KJ. Syrigos KN, et al. Among authors: karapanagiotou em. Cancer Treat Rev. 2009 May;35(3):237-45. doi: 10.1016/j.ctrv.2008.11.002. Epub 2008 Dec 18. Cancer Treat Rev. 2009. PMID: 19100689 Review.

7

Heat shock protein inhibitors and vaccines as new agents in cancer treatment.

Karapanagiotou EM, Syrigos K, Saif MW. Karapanagiotou EM, et al. Expert Opin Investig Drugs. 2009 Feb;18(2):161-74. doi: 10.1517/13543780802715792. Expert Opin Investig Drugs. 2009. PMID: 19236263 Review.

8

Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients.

Karapanagiotou EM, Polyzos A, Dilana KD, Gratsias I, Boura P, Gkiozos I, Syrigos KN. Karapanagiotou EM, et al. Lung Cancer. 2009 Dec;66(3):393-8. doi: 10.1016/j.lungcan.2009.02.006. Epub 2009 Mar 17. Lung Cancer. 2009. PMID: 19282046

9

Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.

Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Tsimboukis S, et al. Among authors: karapanagiotou em. Clin Lung Cancer. 2009 Mar;10(2):106-11. doi: 10.3816/CLC.2009.n.013. Clin Lung Cancer. 2009. PMID: 19362953 Review.

10

Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.

Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A, Syrigos KN. Karapanagiotou EM, et al. Med Oncol. 2010 Jun;27(2):332-8. doi: 10.1007/s12032-009-9214-z. Epub 2009 Apr 17. Med Oncol. 2010. PMID: 19373566

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page